Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11101036 | 0.89 | CYP2D6 (0.54) | TDP1CYP2D6CYP2C19HPGDDRD2 | |
| SCHEMBL1592876 | 0.86 | TDP1 (0.60) | TDP1CYP2D6CYP2C19HPGDDRD2 | |
| SCHEMBL11679951 | 0.84 | CYP2D6 (0.61) | TDP1CYP2D6CYP2C19HPGDDRD2 | |
| SCHEMBL9808080 | 0.84 | ALDH1A1 (0.62) | TDP1CYP2D6CYP2C19HPGDDRD2 | |
| SCHEMBL11103978 | 0.83 | HTR1B (0.62) | HPGDTSHRNPC1ALDH1A1MAPT | |
| SCHEMBL534787 | 0.82 | ALDH1A1 (0.52) | TDP1CYP2D6CYP2C19HPGDDRD2 | |
| SCHEMBL11129324 | 0.82 | TDP1 (0.49) | TDP1CYP2D6CYP2C19HPGDDRD2 | |
| SCHEMBL11127122 | 0.81 | TDP1 (0.51) | TDP1CYP2D6CYP2C19HPGDDRD2 | |
| SCHEMBL5083308 | 0.80 | ALDH1A1 (0.46) | TDP1CYP2D6CYP2C19HPGDALDH1A1 | |
| SCHEMBL10491992 | 0.80 | ALDH1A1 (0.55) | TDP1CYP2D6CYP2C19HPGDDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893087-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. (ES) | 2011-02-22 | — | — | US | claimed |
| US-7879874-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. (ES) | 2011-02-01 | — | — | US | claimed |
| US-20100234332-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | PRAT QUINONES MARIA | 2010-09-16 | — | — | US | claimed |
| US-20070129398-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-06-07 | — | — | US | claimed |
| US-20070129420-A1 | New pyrrolidinium derivatives | ALMIRALL PRODESFARMA SA | 2007-06-07 | — | — | US | claimed |
| US-20070105897-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-05-10 | — | — | US | claimed |
| US-7192978-B2 | Pyrrolidinium derivatives | ALMIRALL PRODESFARMA AG (CH) | 2007-03-20 | — | — | US | claimed |
| US-7122558-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2006-10-17 | — | — | US | claimed |
| EP-1353919-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2006-07-26 | — | — | EP | claimed |
| US-20050282875-A1 | Pyrrolidinium derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2005-12-22 | — | — | US | claimed |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2004-04-15 | — | — | US | claimed |
| EP-1353919-A2 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2003-10-22 | — | — | EP | claimed |
| WO-2002053564-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-11 | — | — | WO | claimed |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| WO-1993016985-A1 | CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-02 | — | — | WO | disclosed |
| EP-0054132-B1 | PYRIMIDONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-10-10 | — | — | EP | disclosed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | disclosed |
| EP-0054132-A1 | Pyrimidones, their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | TDP1 1697/4885CYP2D6 466/4885CYP2C19 715/4885 |
| US-20050282875-A1 | Pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | TDP1 2770/4885CYP2D6 530/4885CYP2C19 766/4885 |
| US-20070129420-A1 | New pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | TDP1 2806/4885CYP2D6 864/4885CYP2C19 1106/4885 |
| US-20070129398-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | NR0B1, NR2C2, NR1I3 | TDP1 4240/4885CYP2D6 274/4885CYP2C19 430/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | TDP1 2409/4885CYP2D6 1344/4885CYP2C19 724/4885 |
| US-20100234332-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NR0B1, NR4A1, NR0B2 | TDP1 4289/4885CYP2D6 284/4885CYP2C19 482/4885 |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | CYP11B1, CYP3A7, CBR1 | TDP1 3321/4885CYP2D6 48/4885CYP2C19 333/4885 |
| US-20070105897-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | NR0B1, NR4A1, NR0B2 | TDP1 4164/4885CYP2D6 293/4885CYP2C19 507/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | TDP1 2705/4885CYP2D6 514/4885CYP2C19 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.